Company News 29 Jul 2024 Orthocell submits Singapore Regulatory Application for Striate+â„¢ Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+â„¢ in Singapore,… Orthocell
Media 24 Jul 2024 Proactive | Interview with Paul Anderson Orthocell Managing Director Paul Anderson speaks with Jonathan Jackson at Proactive about the Company's seven regulatory applications in progress or… Orthocell
Company News 24 Jul 2024 Orthocell Accelerates Global Market Expansion of Striate+â„¢ and Remplirâ„¢ With Seven New Regulatory Applications either in progress or planned Orthocell has announced the accelerated market expansion of Striate+â„¢ and Remplirâ„¢, with seven regulatory applications either in progress or planned… Orthocell
Video 16 Jul 2024 Quarterly Report – Period to 30 June 2024 Orthocell has today published its Quarterly Report for the period ended 30 June 2024. Orthocell
Company News 11 Jul 2024 Orthocell Receives Regulatory Approval to Commence Sales of Striate+â„¢ in Canada Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental… Orthocell
Media 10 Jul 2024 The Australian Business Review | Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue News of Orthocell's record-breaking quarterly and full year revenue has been published in a Special Report in The Australian Business… Orthocell
Media 10 Jul 2024 Business News | Orthocell posts record revenue Orthocell's record revenue for FY24 has been reported in Business News. Orthocell
Media 10 Jul 2024 Proactive Interview | Record-breaking revenue for FY24 Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to discuss the Company's record-breaking revenue for the June… Orthocell
Company News 09 Jul 2024 Orthocell Continues Impressive Growth with Record Quarterly and Yearly Revenue Achieved Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million… Orthocell
Company News, Media 14 Jun 2024 Petra Capital Research Report | June 2024 Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share. Orthocell
